Related Experiment Video
Updated: May 15, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
Published on: August 1, 2025
[Dendritic cells for cancer immunotherapy]
Kazuhiro Kakimi1, Atsushi Kondo, Hirokazu Matsushita
1Department of Immunotherapeutics, The University of Tokyo Hospital.
Abstract:
Dendritic cells (DC) are the antigen presenting cells that initiate and regulate immunity. There are distinct DC subsets with specialized functions spread throughout the body. The type of immune response is determined by the DC subsets involved. Therefore, it is important to understand distinct phenotype and functions of these DC subsets in terms of antigen uptake and processing for MHC class I- and II-restricted presentation and receptors for foreign and endogenous signals. These insights facilitate the direct targeting of antigens to DC surface receptors in vivo rather than ex vivo culturing DC and antigen loading. In addition, novel DC immunotherapies will be in combination with drugs targeting immunological check points.
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

